Liver enzyme holds key to adjusting to high-protein diets
mimics what human ancestors ate before the advent of agriculture. Doctors often prescribe this low-carbohydrate, high-protein diet for their prediabetic patients to help manage weight and glucose levels.

A recent by Pierre Maechler’s group at the University of Geneva, published in the Journal of Biological Chemistry, investigated the role of the liver enzyme glutamate dehydrogenase, or GDH, in short-term adaptation to a high-protein diet.
“The question is how do we adapt when switching to a high-protein diet,” said Maechler. “In particular, what happens if you miss GDH, or if there’s something wrong with it?”
GDH, encoded by the gene GLUD1, is important in amino acid metabolism and gluconeogenesis, a biochemical pathway in the liver that synthesizes glucose from noncarbohydrate precursors. When food is present, the intestine is the main supplier of glucose to the brain, and gluconeogenesis in the liver halts. However, when a constant supply of glucose is unavailable, such as when people fast or partake in low-carbohydrate, high-protein diets, the liver takes over this responsibility by means of gluconeogenesis, mainly by breaking down amino acids from a replenishable source: skeletal muscles.
Maechler’s group initially studied GDH in pancreatic beta cells, which secrete insulin, then expanded their work to the brain and liver. In humans, Maechler explained, known GLUD1 mutations result in GDH gain of function and cause congenital hyperinsulinism/ hyperammonemia syndrome, or HI/HA.
Hyperinsulinism causes hypoglycemia, a severe condition for newborns that may hinder neurodevelopment. As they age, these children are prone to epilepsy and possible mental disabilities. On the other hand, an abnormally high level of ammonia in the blood, hyperammonemia, can be life-threatening. Because GDH gain-of-function mutations result in hyperammonemia, Maechler’s group expected that removing the enzyme would produce a low level of ammonia, or hypoammonemia – however, this was not the case.
“A surprising thing was when we knocked out GLUD1 in the liver; instead of experiencing hypoammonemia, the animals experienced hyperammonemia,” Maechler said, describing the genetically modified mice used in their past studies. “Basically, there’s this kind of bell-shaped effect of GDH function in terms of hyperammonemia.”
Maechler and colleagues also showed that a high-protein diet, coupled with the absence of liver GDH, causes hyperammonemia in mice and, consequently, high ammonia in the urine. This high level of ammonia made the blood more alkaline, and the mice had to significantly reduce their physical activity to maintain proper blood pH through compensatory slowed breathing, or hypoventilation.
“The mice can’t handle fasting periods as well without GDH,” Maechler said.
The researchers also found that while the expression of GDH is homogeneously distributed throughout the liver, the level of its activity is not. They monitored the GDH enzymatic activity in the liver using a and found that GDH is significantly more active in the area near the central vein than near the portal vein.
By cryopreserving the liver and running the NBT assay on fresh liver tissue sections, Maechler explained, they obtained a close representation of what’s happening in a living animal.
In future studies, Maechler plans to investigate GDH function in prediabetic patients, who typically present with steatosis, or fatty livers.
“We showed that you need robust GDH activity to maintain a high-protein diet,” Maechler said.
“But when you have fatty liver, what does your GDH function look like? And can we still recommend a high-protein diet to these patients?”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.